This week, two new leaders at the US Food and Drug Administration announced plans to limit access to covid vaccines, arguing ...

If I am unable to access a vaccine in the future and get a nasty case of COVID, I'll know where to point the finger and so will millions of others.

Government vaccine advisers are meeting to decide if the recipe for COVID-19 vaccines needs updating for this fall and winter ...

The U.S. Food and Drug Administration’s decision to limit COVID vaccines to people 65 and older and others with underlying ...

Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology is currently being evaluated in a phase 1 clinical study of the first needle-free COVID-19 vaccine, having demonstrated ...

A problem very rarely spoken about is the treatments that are promising, but are not developed further. Ben Hargreaves finds that these drug candidates are often left in limbo and never see the ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes. To be known as Viela Bio, the spin-out ...

The death of a young boy with Duchenne muscular dystrophy (DMD) who was treated with Pfizer’s experimental gene therapy in a phase 2 trial has prompted the company to pause dosing in another ...

The FDA has said it intends to reduce or replace animal testing of some medicines, including monoclonal antibodies, with other methods that it hopes will be more relevant to human physiology.

The UK pharma sector has reacted with consternation to the news that the government is proposing to raise the Statutory Scheme payment rate from 15.5% to 32.2% of companies' NHS sales in the ...

Beckley Psytech, just months away from a readout of a phase 2b trial of its psychedelic therapy for treatment-resistant depression (TRD), has built anticipation with new data showing a rapid and ...